MedTrace Logo

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

NCT01634087 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-03-12

No results posted yet for this study

Summary

This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.

Conditions

Interventions

DRUG

Itacitinib

Itacitinib administered orally

DRUG

Placebo

Placebo administered orally

Sponsors & Collaborators

Principal Investigators

  • Victor Sandor, MD · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-01-31
Completion
2013-02-28

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01634087 on ClinicalTrials.gov